Notification

🚨 Trading Holiday 🚨

The NSE and BSE will remain closed for trading and settlement on Monday, April 14, 2025, on account of Dr. B. R. Ambedkar Jayanti.

Open a Free Demat Account

Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.

Trade Now, Pay Later with up to 4x

Never miss a good trading opportunity due to low funds with our MTF feature.

Track Market Movers Instantly

Stay updated with real-time data. Get insights at your fingertips.

NSE BSE

Trade Nowopens in a new tab

P. E. Analytics Limited Share Price

₹ 216 4.00 (1.88%)

Apr 15 2025 03:04 PM Miscellaneous NSE: PROPEQUITY

P. E. Analytics Limited Share Price Update

As of the latest trading session, P. E. Analytics Limited share price is currently at 216, which is up by 4.00 from its previous closing. Today, the stock has fluctuated between 215.00 and 216.00. Over the past year, P. E. Analytics Limited has achieved a return of -26.89 %. In the last month alone, the return has been -5.77 %. Read More...

P. E. Analytics Limited Performance

Day Range

Low215.00 High216.00

216.00

52 Week Range

Low 188.80 High 332.00

216.00

P. E. Analytics Limited Share Price

8735

208730

PROPEQUITY

Compare to down-arrow

View

Display

Studies

No Data Available

Open Price

215.00 Prev. Close

212.00 Volume (Shares)

1800.00

Total traded value

3.88 Upper Circuit

254.40 Lower Circuit

169.60

Note: The current prices & values are delayed, Loginopens in a new tab to your account for live updates.

P. E. Analytics Limited Fundamentals

(Standalone)

Market Cap (Cr)	226.41
PE Ratio (TTM)	24.51
Book Value / Share	69.86
Beta	0.65

ROE	13.20%
EPS (TTM)	8.65
Dividend Yield	0.00%
Net Profit Qtr (Cr)	0.00

P. E. Analytics Limited Financials

Key Results
Key Ratios
Balance sheet
Cash Flow
Competition

Revenue

Net income

Particulars	MAR 2024 (Values in Cr)
Revenue	22.01
Operating Expense	14.01
Net Profit	9.07
Net Profit Margin (%)	41.20
Earnings Per Share (EPS)	8.65
EBITDA	12.66
Effective Tax Rate (%)	26.32

Particulars	MAR 2023 (Values in Cr)
Revenue	20.39
Operating Expense	11.53
Net Profit	8.97
Net Profit Margin (%)	43.99
Earnings Per Share (EPS)	8.56
EBITDA	12.28
Effective Tax Rate (%)	25.37

Particulars	MAR 2022 (Values in Cr)
Revenue	23.91
Operating Expense	13.42
Net Profit	9.31
Net Profit Margin (%)	38.93
Earnings Per Share (EPS)	10.67
EBITDA	12.54
Effective Tax Rate (%)	23.81

Particulars	MAR 2021 (Values in Cr)
Revenue	18.01
Operating Expense	10.44
Net Profit	6.71
Net Profit Margin (%)	37.25
Earnings Per Share (EPS)	7.73
EBITDA	9.30
Effective Tax Rate (%)	25.44

Particulars	MAR 2020 (Values in Cr)
Revenue	15.62
Operating Expense	15.73
Net Profit	1.17
Net Profit Margin (%)	7.49
Earnings Per Share (EPS)	365.00
EBITDA	1.79
Effective Tax Rate (%)	22.51

Particulars	MAR 2024 (Values in Cr)
Book Value / Share	73.16
ROE %	16.41
ROCE %	21.87
Total Debt to Total Equity	0.00
EBITDA Margin	40.52

Particulars	MAR 2023 (Values in Cr)
Book Value / Share	62.52
ROE %	17.57
ROCE %	23.17
Total Debt to Total Equity	0.00
EBITDA Margin	49.88

Particulars	MAR 2022 (Values in Cr)
Book Value / Share	52.71
ROE %	17.00
ROCE %	21.98
Total Debt to Total Equity	0.00
EBITDA Margin	52.85

Particulars	MAR 2024 (Values in Cr)
Book Value / Share	69.86
ROE %	13.20
ROCE %	17.66
Total Debt to Total Equity	0.00
EBITDA Margin	57.47

Particulars	MAR 2023 (Values in Cr)
Book Value / Share	61.21
ROE %	15.03
ROCE %	19.80
Total Debt to Total Equity	0.00
EBITDA Margin	60.23

Particulars	MAR 2022 (Values in Cr)
Book Value / Share	52.66
ROE %	22.76
ROCE %	29.19
Total Debt to Total Equity	0.00
EBITDA Margin	52.66

Particulars	MAR 2021 (Values in Cr)
Book Value / Share	8318.84
ROE %	25.69
ROCE %	33.27
Total Debt to Total Equity	0.00
EBITDA Margin	51.86

Particulars	MAR 2020 (Values in Cr)
Book Value / Share	6029.46
ROE %	20.25
ROCE %	22.65
Total Debt to Total Equity	0.00
EBITDA Margin	39.24

Particulars	MAR 2024 (Values in Cr)
Cash & Short Term Investments	68.54
Total Assets	87.36
Total Liabilities	87.36
Total Equity	77.54
Share Outstanding	10482104
Price to Book Ratio	4.12
Return on Assets (%)	12.76
Return on Capital (%)	14.38

Particulars	MAR 2023 (Values in Cr)
Cash & Short Term Investments	59.64
Total Assets	73.15
Total Liabilities	73.15
Total Equity	65.87
Share Outstanding	10482104
Price to Book Ratio	2.46
Return on Assets (%)	14.05
Return on Capital (%)	15.6

Particulars	MAR 2022 (Values in Cr)
Cash & Short Term Investments	62.14
Total Assets	74.60
Total Liabilities	74.60
Total Equity	55.26
Share Outstanding	10482104
Price to Book Ratio	0.00
Return on Assets (%)	12.56
Return on Capital (%)	16.95

Particulars	MAR 2024 (Values in Cr)
Cash & Short Term Investments	68.30
Total Assets	81.49
Total Liabilities	81.49
Total Equity	73.23
Share Outstanding	10482104
Price to Book Ratio	4.12
Return on Assets (%)	11.12
Return on Capital (%)	12.38

Particulars	MAR 2023 (Values in Cr)
Cash & Short Term Investments	59.23
Total Assets	70.81
Total Liabilities	70.81
Total Equity	64.16
Share Outstanding	10482104
Price to Book Ratio	2.46
Return on Assets (%)	12.66
Return on Capital (%)	13.98

Particulars	MAR 2022 (Values in Cr)
Cash & Short Term Investments	62.11
Total Assets	74.49
Total Liabilities	74.49
Total Equity	55.19
Share Outstanding	10482104
Price to Book Ratio	0.00
Return on Assets (%)	12.49
Return on Capital (%)	16.87

Particulars	MAR 2021 (Values in Cr)
Cash & Short Term Investments	21.08
Total Assets	31.71
Total Liabilities	31.71
Total Equity	26.62
Share Outstanding	32024
Price to Book Ratio	0.00
Return on Assets (%)	21.16
Return on Capital (%)	25.21

Particulars	MAR 2020 (Values in Cr)
Cash & Short Term Investments	19.13
Total Assets	29.50
Total Liabilities	29.50
Total Equity	25.62
Share Outstanding	42000
Price to Book Ratio	0.00
Return on Assets (%)	3.96
Return on Capital (%)	4.57

Particulars	MAR 2024 (Values in Cr)
Net Income	15.78
Cash from Operations	9.74
Cash from Investing	3.53
Cash from Financing	0.00
Net change in Cash	8.90
Free Cash Flow	10.21

Particulars	MAR 2023 (Values in Cr)
Net Income	14.21
Cash from Operations	10.16
Cash from Investing	3.72
Cash from Financing	-12.55
Net change in Cash	-2.50
Free Cash Flow	10.69

Particulars	MAR 2022 (Values in Cr)
Net Income	12.32
Cash from Operations	23.62
Cash from Investing	1.25
Cash from Financing	19.26
Net change in Cash	41.06
Free Cash Flow	23.89

Particulars	MAR 2024 (Values in Cr)
Net Income	12.30
Cash from Operations	8.70
Cash from Investing	3.53
Cash from Financing	0.00
Net change in Cash	9.06
Free Cash Flow	9.16

Particulars	MAR 2023 (Values in Cr)
Net Income	12.02
Cash from Operations	9.11
Cash from Investing	3.72
Cash from Financing	-12.55
Net change in Cash	-2.87
Free Cash Flow	9.64

Particulars	MAR 2022 (Values in Cr)
Net Income	12.22
Cash from Operations	23.59
Cash from Investing	1.25
Cash from Financing	19.26
Net change in Cash	41.03
Free Cash Flow	23.86

Particulars	MAR 2021 (Values in Cr)
Net Income	9.00
Cash from Operations	12.16
Cash from Investing	-2.09
Cash from Financing	-5.72
Net change in Cash	1.94
Free Cash Flow	12.36

Particulars	MAR 2020 (Values in Cr)
Net Income	1.51
Cash from Operations	-0.70
Cash from Investing	3.58
Cash from Financing	0.00
Net change in Cash	2.46
Free Cash Flow	-0.46

Company Name	Price	P/E	P/B	Market Cap	52 Week Low/High
KESORAM INDUSTRIES LTD	3.77	0.00	-3.68	117.14	3.66 / 11.79
MODI RUBBER LTD	104.70	11.67	0.47	262.17	86.05 / 156.75
THOMAS COOK (INDIA) LTD	131.40	24.89	4.02	6187.54	118.10 / 264.00
RAIN INDUSTRIES LIMITED	137.80	0.00	0.69	4634.90	117.30 / 196.95

Company Name	Price	P/E	P/B	Market Cap	52 Week Low/High
FGP LTD.	8.98	47.26	2.87	10.68	5.85 / 14.18
KESORAM INDUSTRIES LTD	3.77	0.00	0.51	117.14	3.66 / 11.79
MPIL CORPORATION LTD.	620.00	0.00	2.36	35.34	506.00 / 1033.00
MODI RUBBER LTD	104.70	24.29	0.97	262.17	86.05 / 156.75

Technicals

EMA & SMA
Resistance and Support
Price Change Analysis

Bullish Moving Averages -

Bearish Moving Averages -

5 Days 213.90
26 Days 225.80
10 Days 217.30
50 Days 237.00
12 Days 218.50
100 Days 251.50
20 Days 222.80
200 Days 259.20

212.07
PIVOT

First Resistance	212.13
Second Resistance	212.27
Third Resistance	212.33

First Support	211.93
Second Support	211.87
Third Support	211.73

RSI	40.67
MACD	-7.31
Commodity Channel Index (CCI)	-105.93

ADX	22.37
Williams % R	-69.55

P. E. Analytics Limited Future

Future: Price

25 May

0 100 200 300 400 500 600

Discount/Premium

25 May

0 1 2 3 4 5 6 7

Active Calls

25 May

0 500 1000 1500 2000 2500 3000

Active Puts

25 Jul

0 500 1000 1500 2000 2500

Stock Holding

View Live Stock Screeners

Holding

Public

22.31 Promoter Holdings

67.12 FII

10.56 DII

0.0 Promoter Shares(Pledge Percentage)

0.0

Name	Category	Shares	Shares%
Samir Jasuja	Shareholding of Promoter and Promoter Group	7035428.0	67.12
Barca Global Master Fund Lp	Public Shareholding	504600.0	4.81
Hornbill Orchid India Fund	Public Shareholding	404400.0	3.86
Vaibhav Sunil Kapur	Public Shareholding	211200.0	2.01
Seema Krishnarao Toraskar	Public Shareholding	191400.0	1.83
Rajeshkumar Mannarapadavathu Sasidharan	Public Shareholding	121800.0	1.16
Braham Arenja	Public Shareholding	114600.0	1.09
Vaishali Jasuja	Shareholding of Promoter and Promoter Group	271.0	0.0

P. E. Analytics Limited

Ex-Date	Dividend Amt.	Dividend Type	Record Date	Instrument Type

Learn More About Stocks

Dr Reddy’s Denies Workforce Reduction Claims Amid Cost-Cut Rumours

Dr Reddy’s Laboratories rejects claims of reducing workforce costs by 25%, asserting no such plans or internal directives.

15 Apr, 2025 | 3 Min. read

Glenmark, Sun Pharma, Zydus Recall Drugs in US over Compliance Issues

Glenmark, Sun Pharma, and Zydus recall multiple drug batches in the US following manufacturing deviations and contamination concerns as per USFDA enforcement reports.

15 Apr, 2025 | 3 Min. read

HAL Denies Selecting PwC for R&D Benchmarking Amid Ongoing Bids

HAL clarifies no consultancy firm has been finalised for R&D benchmarking amid social media buzz about PwC. Selection process still ongoing via GeM portal.

15 Apr, 2025 | 3 Min. read

Aurobindo Pharma Gets USFDA Nod for Generic Xarelto 2.5mg Tablets

Aurobindo Pharma receives USFDA approval to launch generic Xarelto 2.5mg in Q1 FY26, targeting $447 million US market; higher strengths also gain tentative nod.

15 Apr, 2025 | 3 Min. read

IndiGo Becomes World’s Most Valuable Airline With $23.4 Billion Market Cap

IndiGo surpasses global peers to become the most valuable airline by market cap at $23.4 billion, pushing InterGlobe Aviation share price to record highs in 2025.

11 Apr, 2025 | 3 Min. read

SRF Ltd. Commissions New Agrochemical Unit in Dahej Worth Rs.239 Crore

SRF Ltd. starts new agrochemical facility in Dahej, Gujarat with Rs.239 crore investment. Phase 1 operational, full commissioning set for April 2025.

11 Apr, 2025 | 3 Min. read

Tata Motors’ JLR India Achieves Record Sales in FY25 at 6,183 Units

JLR India posts record-breaking FY25 retail sales of 6,183 units, up 40%. Defender leads growth, boosting Tata Motors share price sentiment.

11 Apr, 2025 | 4 Min. read

Biocon Gets USFDA Approval for Jobevne, Expands Oncology Portfolio

Biocon Biologics receives USFDA nod for cancer drug Jobevne, a bevacizumab biosimilar. Oncology portfolio in US grows, boosting Biocon Ltd. share price outlook.

11 Apr, 2025 | 3 Min. read